CM
CM Management Portfolio holdings
AUM
$110M
This Quarter Return
-5.23%
1 Year Return
+9.76%
3 Year Return
+99.54%
5 Year Return
–
10 Year Return
–
AUM
$99.5M
AUM Growth
+$99.5M
(-11%)
Cap. Flow
-$5M
Cap. Flow
% of AUM
-5.02%
Top 10 Holdings %
Top 10 Hldgs %
41.5%
Holding
62
New
5
Increased
25
Reduced
4
Closed
8
Top Buys
| 1 |
Cytokinetics
CYTK
|
$1.61M |
| 2 |
Warner Bros
WBD
|
$858K |
| 3 |
Stanley Black & Decker
SWK
|
$769K |
| 4 |
Freeport-McMoran
FCX
|
$757K |
| 5 |
Herc Holdings
HRI
|
$671K |
Top Sells
| 1 |
Royalty Pharma
RPRX
|
$4.08M |
| 2 |
Copa Holdings
CPA
|
$2.64M |
| 3 |
B
Barrick Mining Corporation
B
|
$1.94M |
| 4 |
Pan American Silver
PAAS
|
$1.62M |
| 5 |
ClearPoint Neuro
CLPT
|
$1.37M |
Sector Composition
| 1 | Healthcare | 36.19% |
| 2 | Materials | 10.41% |
| 3 | Industrials | 10.18% |
| 4 | Technology | 9.3% |
| 5 | Financials | 9.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Coherus Oncology, Inc. Common Stock
CHRS
$146M
| $1.73M | 1.74% |
2,147,500
+97,500
| +5% | +$78.7K |
|
27
Iovance Biotherapeutics
IOVA
$800M
| $1.67M | 1.67% |
500,000
+200,000
| +67% | +$666K |
|
|
28
Warner Bros
WBD
$29.5B
| $1.61M | 1.62% |
150,000
+80,000
| +114% | +$858K |
|
|
29
Cytokinetics
CYTK
$5.98B
| $1.61M | 1.62% |
+40,000
| New | +$1.61M |
|
30
Atea Pharmaceuticals
AVIR
$275M
| $1.5M | 1.5% |
500,000
+200,000
| +67% | +$598K |
|
31
Cohu
COHU
$899M
| $1.47M | 1.48% |
100,000
+30,000
| +43% | +$441K |
|
32
Heron Therapeutics
HRTX
$204M
| $1.32M | 1.33% |
600,000
-100,000
| -14% | -$220K |
|
33
Coya Therapeutics
COYA
$112M
| $1.29M | 1.3% |
200,000
+40,000
| +25% | +$259K |
|
34
Xoma
XOMA
$421M
| $1.28M | 1.28% |
64,000
+9,000
| +16% | +$179K |
|
35
Acadia Pharmaceuticals
ACAD
$4.34B
| $1.25M | 1.25% |
75,000
+5,000
| +7% | +$83.1K |
|
|
SVC
36
Service Properties Trust
SVC
$456M
| $1.17M | 1.18% |
450,000
| – | – |
|
37
AMCON Distributing
DIT
$72M
| $1.03M | 1.03% |
8,754
+421
| +5% | +$49.4K |
|
38
Cytosorbents Corp
CTSO
$61.5M
| $954K | 0.96% |
954,076
+254,076
| +36% | +$254K |
|
39
Eledon Pharmaceuticals
ELDN
$155M
| $932K | 0.94% |
275,000
| – | – |
|
|
40
Stanley Black & Decker
SWK
$11.3B
| $769K | 0.77% |
+10,000
| New | +$769K |
|
41
Lantern Pharma
LTRN
$46.3M
| $708K | 0.71% |
200,000
| – | – |
|
|
42
Herc Holdings
HRI
$4.2B
| $671K | 0.67% |
+5,000
| New | +$671K |
|
43
Hasbro
HAS
$11.1B
| $615K | 0.62% |
10,000
-10,000
| -50% | -$615K |
|
44
Nektar Therapeutics
NKTR
$543M
| $544K | 0.55% |
800,000
+50,000
| +7% | +$34K |
|
45
Femasys
FEMY
$12M
| $531K | 0.53% |
425,000
| – | – |
|
46
Curis
CRIS
$21.5M
| $504K | 0.51% |
240,000
+20,000
| +9% | +$42K |
|
|
OSTX
47
OS Therapies Incorporated
OSTX
$66.5M
| $462K | 0.46% |
300,000
+189,956
| +173% | +$293K |
|
48
Dell
DELL
$83.9B
| $456K | 0.46% |
+5,000
| New | +$456K |
|
49
Elicio Therapeutics
ELTX
$169M
| $339K | 0.34% |
55,000
+15,000
| +38% | +$92.4K |
|
50
Assertio
ASRT
$78M
| $320K | 0.32% |
475,000
+75,000
| +19% | +$50.6K |
|